Drug intelligence / Profile preview

ixekizumab

Development stage: Approved
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Ixekizumab is a humanized monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine involved in inflammatory processes. It is used to treat moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Developed by Eli Lilly, ixekizumab works by inhibiting IL-17A, thereby reducing inflammation and improving symptoms in autoimmune diseases.

Brand names: TALTZ拓咨
Other names: 依奇珠单抗

Targets

IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on ixekizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ixekizumab.

Explore the full profile